|
Cox regression
|
Competing risk regression
|
---|
Crude HR
|
Adjusted HR
|
Crude sHR
|
Adjusted sHR
|
---|
Opportunistic infections
|
SLE
|
1 (reference)
|
1 (reference)
|
1 (reference)
|
1 (reference)
|
PM/DM
|
1.38 (1.26–1.51)
|
1.18 (1.08–1.29)
|
1.22 (1.11–1.34)
|
1.17 (1.07–1.29)
|
SSc
|
0.75 (0.67–0.85)
|
0.58 (0.51–0.65)
|
0.70 (0.62–0.78)
|
0.67 (0.59–0.75)
|
RA
|
0.61 (1.26–1.51)
|
0.46 (0.44–0.48)
|
0.62 (0.59–0.65)
|
0.59 (0.57–0.62)
|
pSS
|
0.57 (0.54–0.60)
|
0.42 (0.39–0.44)
|
0.58 (0.55–0.61)
|
0.56 (0.53–0.59)
|
Non-herpes zoster opportunistic infections
|
SLE
|
1 (reference)
|
1 (reference)
|
1 (reference)
|
1 (reference)
|
PM/DM
|
1.63 (1.41–1.89)
|
1.22 (1.05–1.42)
|
1.44 (1.24–1.68)
|
1.22 (1.05–1.43)
|
SSc
|
0.83 (0.68–1.01)
|
0.55 (0.45–0.67)
|
0.77 (0.64–0.93)
|
0.65 (0.54–0.79)
|
RA
|
0.50 (0.47–0.54)
|
0.33 (0.30–0.36)
|
0.51 (0.47–0.55)
|
0.45 (0.42–0.49)
|
pSS
|
0.38 (0.34–0.42)
|
0.25 (0.22–0.28)
|
0.39 (0.34–0.43)
|
0.35 (0.31–0.39)
|
- HR hazard ratio, sHR subdistribution hazard ratio, SLE systemic lupus erythematosus, RA rheumatoid arthritis, pSS primary Sjögren’s syndrome, SSc systemic sclerosis, PM/DM polymyositis/dermatomyositis